Literature DB >> 8295006

Discriminated release of a hippurate-like radiometal chelate in nontarget tissues for target-selective radioactivity localization using pH-dependent dissociation of reduced antibody.

Y Arano1, T Inoue, T Mukai, K Wakisaka, H Sakahara, J Konishi, A Yokoyama.   

Abstract

UNLABELLED: To achieve high and selective target radioactivity localization by monoclonal antibodies (Mabs) labeled with metallic radionuclides, the discriminated release of a hippurate-like radiometal chelate in nontarget tissues was performed using chemically modified Mabs.
METHODS: The disulfide bonds of a Mab against osteogenic sarcoma (OST7, IgG1) were reduced and 67Ga chelate of succinyldeferoxamine (SDF) was conjugated proximal to the Mab molecule via an ester bond with exposed thiol groups (67Ga-DFO-MESS-redOST7), which would impair esterase access to the ester bond of 67Ga-DFO-MESS-redOST7 due to the steric interference induced by bulky antibody molecule, stabilizing the ester bond in plasma and on the target cell's surface. Gallium-67-SDF was also conjugated to OST7 via an ester bond with 2-iminothiolane to render the ester bond in a position distal from the OST7 molecule (67Ga-DFO-MESS-IT-OST7).
RESULTS: Although SDS-PAGE analyses of 67Ga-DFO-MESS-redOST7 showed a partial cleavage of its disulfide bonds, size-exclusion HPLC and cell binding assays indicated that the IgG structure and immunoreactivity of this conjugate were preserved in a neutral buffer and plasma of the systemic circulation.
CONCLUSION: The present radiochemical design of an antibody utilizing pH-dependent dissociation would constitute a promising approach in establishing selective target radioactivity localization by Mabs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8295006

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  2 in total

1.  A novel immunoscintigraphy technique using metabolizable linker with angiotensin II treatment.

Authors:  Y Nakamoto; H Sakahara; T Saga; N Sato; S Zhao; Y Arano; Y Fujioka; H Saji; J Konishi
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

2.  Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.

Authors:  Taiki Kurino; Reiko Matsuda; Ayu Terui; Hiroyuki Suzuki; Tomomi Kokubo; Tomoya Uehara; Yasushi Arano; Akihiro Hisaka; Hiroto Hatakeyama
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.